Inspire Pharmaceuticals, Inc.

Aggressively Advance Our Product Candidates.
We focus significant energy and resources to rapidly and efficiently develop our existing product candidates. We target therapeutic markets and pursue product candidates where current therapy is not optimal and where we perceive significant market opportunities to exist.

Establish Strategic Relationships that Enhance and Complement Our Own Product Development and Commercial Organization.
Collaborations are, and we believe will continue to be, a key component of our corporate strategy. We have entered, or plan to enter, into alliances with pharmaceutical companies for the commercialization of our products, especially to address markets outside North America where we do not intend to develop infrastructure to commercialize our products. In addition, we intend to continue to develop alliances with leading pharmaceutical companies to enrich our product candidate pipeline and optimize our commercial efforts.
Successfully Commercialize Products Through a Concentrated Sales and Marketing Effort in Our Target Markets.
A key element of our strategy is to be involved in the sales and marketing activities of our products in North America. To that end, we have developed a specialty sales and marketing organization to support the commercialization of Elestat^®, Restasis^®, and AzaSite^® to ophthalmologists, optometrists, allergists, pediatricians and primary care physicians in the United States.
Develop or In-License New Products to Strengthen Our Core Therapeutic Areas of Ophthalmology and Pulmonary.
Our research focus is to discover new pharmaceutical products that expand beyond our P2 receptor technology. We have internal programs and sponsored research and development agreements with universities to discover, develop and in-license new pharmaceutical products. In addition, we continue to be opportunistic with regard to in-licensing products from biotechnology and biopharmaceutical companies in various stages of development in our core therapeutic areas.
Build Intellectual Property Around Our Product Candidates.
We have a substantial intellectual property position related to our technology. We currently have more than 75 issued patents. We also have other U.S. patents pending and multiple foreign patents issued and pending. We intend to continue to pursue an aggressive patent strategy to protect our expanding proprietary discoveries.

Page last updated: 30-Jul-2008